← 返回

淫羊藿(Epimedium brevicornu Maxim.)提取物通过 cGAS-STING 通路激活 NK 细胞对抗肝细胞癌

英文原题:Epimedium brevicornu Maxim. extract activates natural killer cells against hepatocellular carcinoma via the cGAS-STING pathway.

查看英文原题

Epimedium brevicornu Maxim. extract activates natural killer cells against hepatocellular carcinoma via the cGAS-STING pathway.

PubMed 2025/11/21(内容时间) Front Pharmacol Q1 · IF 5.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

EPE 通过激活 cGAS-STING 信号通路激活 NK 细胞,从而发挥抗 HCC 作用。这表明 EPE 可能作为一种潜在的免疫治疗剂,为 HCC 的治疗提供新的治疗视角。

研究思路结论见上方概要

淫羊藿(Epimedium brevicornu Maxim.)作为一种传统中草药,已显示出对肝细胞癌(HCC)的显著治疗作用,其黄酮类化合物通过多种机制发挥抗HCC活性。然而,淫羊藿的抗HCC作用是否通过激活自然杀伤(NK)细胞介导,目前尚不清楚。

通过酶联免疫吸附试验(ELISA)和流式细胞术评估EPE对NK细胞活性的影响。构建NK-92细胞与K562靶细胞的共培养模型,采用Calcein-AM释放试验评估EPE增强的NK细胞毒性。采用小鼠HCC皮下异种移植模型在体内证明EPE靶向NK细胞活化抗HCC的作用。进行NK1.1细胞耗竭实验以进一步证实NK细胞依赖性抗肿瘤机制。最后,采用Western blotting、流式细胞术、分子对接、细胞热位移试验(CETSA)和药物亲和反应靶稳定性试验(DARTS)阐明EPE激活NK细胞的潜在分子机制。

EPE显著促进NK-92细胞中IFN-、Granzyme B和Perforin的合成与释放,并提高NK-92细胞及人原代NK细胞表面活化受体NKG2D的表达。用EPE处理人原代NK细胞可增加CD56 bright CD16 dim和CD56 dim CD16 bright NK细胞亚群的比例。Calcein释放实验表明,EPE增强了NK细胞对K562细胞的细胞毒活性。利用皮下HCC异种移植小鼠模型的研究证实,EPE有效抑制肿瘤生长,促进肿瘤细胞死亡,并显著提高HCC荷瘤小鼠脾脏和肿瘤组织中NK细胞活化标志物IFN-和CD107a的水平。NK1.1细胞清除实验证明,清除NK1.1细胞显著减弱了EPE的抗HCC作用,进一步表明EPE在体内通过特异性靶向并激活NK细胞发挥抗肿瘤作用。机制研究揭示,EPE促进NK细胞中IFN-的释放,显著提高STING和IRF3的磷酸化水平。同时,免疫荧光结果表明,EPE显著上调HCC小鼠肿瘤组织内肿瘤浸润NK细胞中p-STING蛋白的表达水平。高效液相色谱(HPLC)显示,4H-1-Benzopyran-4-one、Epimedin A1、Epimedin A、Epimedin B、Epimedin C、Icariin、Baohuoside是EPE中含量较高的化合物,且Epimedin C与STING之间具有较强的结合能力。此外,Epimedin C降低STING的热稳定性,但增加其对蛋白消化酶的抵抗力。

展开英文摘要原文

Epimedium brevicornu : Maxim., a traditional Chinese botanical drug, has shown significant therapeutic effects against hepatocellular carcinoma (HCC), with its flavonoid compounds exhibiting anti-HCC activity through various mechanisms. However, it remains unclear whether the anti-HCC effects of Epimedium are mediated through the activation of natural killer (NK) cells.

The impact of EPE on NK cell activity was assessed via Enzyme-Linked Immunosorbent Assay (ELISA) and flow cytometry. A co-culture model of NK-92 cells with K562 target cells was constructed to evaluate EPE-enhanced NK cytotoxicity using Calcein-AM release assay. A murine HCC subcutaneous xenograft model was employed to demonstrate EPE-targeted NK cell activation against HCC in vivo . NK1.1 cell depletion experiment was conducted to further confirm the NK cell-dependent anti-tumor mechanism. Finally, Western blotting, flow cytometry, molecular docking, Cellular thermal shift assay (CETSA) and Drug affinity responsive target stability assay (DARTS) were used to elucidate the underlying molecular mechanisms of EPE in activating NK cell.

EPE significantly promoted the synthesis and release of IFN- , Granzyme B, and Perforin in NK-92 cells and increased the expression of the activating receptor NKG2D on the NK-92 cell and human primary NK cells surface. Treatment of human primary NK cells with EPE increased the proportion of the CD56 bright CD16 dim and CD56 dim CD16 bright NK cell subsets. Calcein release assays demonstrated that EPE enhanced the cytotoxic activity of NK cells against K562 cells. Studies utilizing a murine model of subcutaneous HCC xenografts confirmed that EPE effectively inhibited tumor growth, promoted tumor cell death, and significantly elevated the levels of the NK cell activation markers IFN- and CD107a in the spleen and tumor tissues of HCC-bearing mice. NK1.1 cell depletion experiment proved that depletion of NK1.1 cells significantly attenuated the anti-HCC effect of EPE, further demonstrating that the EPE exerts its anti-tumor action by specifically targeting and activating NK cells in vivo . Mechanistic studies revealed that EPE promoted IFN- release in NK cells, significantly increased the phosphorylation levels of STING and IRF3. Concurrently, immunofluorescence results indicated that EPE significantly upregulated the expression level of p-STING protein in tumor-infiltrating NK cells within the tumor tissues of HCC mice. High Performance Liquid Chromatograph (HPLC) revealed that 4H-1-Benzopyran-4-one, Epimedin A1, Epimedin A, Epimedin B, Epimedin C, Icariin, Baohuoside were compounds with higher content in EPE, and there is a strong binding ability between Epimedin C and STING. Moreover, Epimedin C decrease the thermostability of STING but increase the resistance to protein-digesting enzymes.

EPE exerts anti- HCC effects by activating NK cells through the activation of the cGAS-STING signaling pathway. This suggests that EPE may serve as a potential immunotherapeutic agent, offering novel therapeutic perspectives for the treatment of HCC.

论文信息

作者
Liu L、Zhan X、Wang X、Wen J、He C、Chen X、Guo Y、Wang X
单位
School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu, Chengdu, China.China
期刊
Frontiers in pharmacology2025
原文标识
PubMed 41357886 · DOI 10.3389/fphar.2025.1681650